{"filing":{"accession_number":"0001628280-26-052877","cik":"0001651308","ticker":"BEIGF","company_name":"BeOne Medicines Ltd.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"bgne-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/bgne-20260805.htm"},"events":[{"id":24933,"run_id":22605,"accession_number":"0001628280-26-052877","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"BeOne Medicines disclosed its Q2 2026 financial results via press release attached as Exhibit 99.1, reporting total global revenues of $1.7 billion (30% YoY growth), GAAP diluted EPS of $2.05, and raised full-year 2026 guidance to $6.6–$6.8 billion in total revenue. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25634,"accession_number":"0001628280-26-052877","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"BeOne Medicines disclosed its Q2 2026 financial results via press release attached as Exhibit 99.1, reporting total global revenues of $1.7 billion (30% YoY growth), GAAP diluted EPS of $2.05, and raised full-year 2026 guidance to $6.6–$6.8 billion in total revenue. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:36:28.526051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25634,"accession_number":"0001628280-26-052877","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"BeOne Medicines disclosed its Q2 2026 financial results via press release attached as Exhibit 99.1, reporting total global revenues of $1.7 billion (30% YoY growth), GAAP diluted EPS of $2.05, and raised full-year 2026 guidance to $6.6–$6.8 billion in total revenue. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:36:28.526051+00:00","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-08-05"}]}